Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
US9763956B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9763956-B2 |
| Application number | US-201314409138-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2013 |
| Priority date | Jun 19, 2012 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method comprising administering to a subject having cancer a bromodomain inhibitor, with or without a Bcl-2 inhibitor, and a Notch pathway inhibitor, in an effective amount to treat the cancer, wherein the cancer is characterized by the presence of a Notch pathway activation mutation. 2. The method of claim 1 , wherein the bromodomain inhibitor, without the Bcl-2 inhibitor, and the Notch pathway inhibitor are administered. 3. The method of claim 1 , wherein the bromodomain inhibitor, the Bcl-2 inhibitor and the Notch pathway inhibitor are administered. 4. The method of claim 3 , wherein the bromodomain inhibitor, the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially. 5. The method of claim 1 , further comprising identifying the subject as a subject having cancer characterized by the presence of a Notch pathway activation mutation. 6. The method of claim 2 , wherein the bromodomain inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially. 7. The method of claim 3 , wherein the bromodomain inhibitor and the Bcl-2 inhibitor are administered concurrently or sequentially. 8. The method of claim 3 , wherein the Bcl-2 inhibitor is G3139, GX15-070, ABT-737 or ABT-199. 9. The method of claim 1 , wherein the bromodomain inhibitor is a BET inhibitor. 10. The method of claim 1 , wherein the bromodomain inhibitor is JQ1 or a derivative thereof. 11. The method of claim 1 , wherein the Notch pathway inhibitor is a gamma secretase inhibitor. 12. The method of claim 3 , wherein the bromodomain inhibitor, the Bcl-2 inhibitor and/or the Notch pathway inhibitor is an siRNA, shRNA, or antisense nucleic acid molecule.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
interfering nucleic acids [NA] · CPC title
condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9763956B2 cover?
- The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.
- Who is the assignee on this patent?
- Broad Inst Inc, Brigham & Womens Hospital Inc, Massachusetts Gen Hospital, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/551. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).